A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres

Peptides

Volumn 30, Issue 10, 2009, Pages 1874-1881

  Gao, Zhihui ^a   Tang, Yu ^a   Chen, Jiaqi ^a   Bai, Ru ^a   Zhang, Qi ^a   Hou, Yuanyuan ^a   Lu, Yaxin ^a   Bai, Gang ^a,b  

^a NANKAI UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Antihyperglycemic; DPP IV resistant analog; GLP 1; Insulinotropic; Poly (d,l lactic co glycolic acid) microspheres (PLGA MS); Type 2 diabetes

Indexed keywords

ALLOXAN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LYSYLHISTIDYLALANYLGLUTAMATYLGLYCYLTHREONYLPHENYLALANYLTHREONYLALANYLSERYLVALYLSERYLSERYLTYROSYLEUCYLGLUTAMATYLGLYCYLGLUTAMYLALANYLALANYLLYSYLGLUTAMATYLPHENYLALANYLISOLEUCYLALANYLTRYPTOPHANYLLEUCYLVALYLLYSYLGLYCYLARGININE; MICROSPHERE; OIL; POLYGLACTIN; UNCLASSIFIED DRUG;

ALLOXAN DIABETES MELLITUS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENCAPSULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SOLVENT EXTRACTION;

ANIMALS; ANTIGENS, CD26; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DRUG COMPOUNDING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; LACTIC ACID; MICE; MICROSPHERES; POLYGLYCOLIC ACID; RATS; RATS, WISTAR;

MUS; RATTUS;

EID: 70349325502     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.07.020     Document Type: Article

References (34)

1. Andersen D.K., Elahi D., Brown J.C., Tobin J.D., and Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 62 1 (1978) 152-161
2. Burington R.S. Handbook of mathematical tables and formulas (1973), McGraw-Hill, New York
3. Buse J.B., Rosenstock J., Sesti G., Schmidt W.E., Montanya E., Brett J.H., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAN-6). Lancet 374 9683 (2009) 4-6
4. Chen J., Bai G., Yang Y., Geng P., Cao Y., and Zhu Y. Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay. Peptides 28 4 (2007) 928-934
5. Choi S., Baudys M., and Kim S.W. Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats. Pharm Res 21 5 (2004) 827-831
6. Chou J.Z., Place G.D., Waters D.G., Kirkwood J.A., and Bowsher R.R. A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. J Pharm Sci 86 7 (1997) 768-773
7. David R., Macnair C., and Kenny A.J. Proteins of the kidney microvillar membrane: The amphipatic form of dipeptidyl peptidase IV. Biochem J 179 (1979) 379-395
8. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 9 (2004) 2181-2189
9. Deacon C.F., Johnsen A.H., and Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 3 (1995) 952-957
10. Diaz R.V., Llabrés M., and Evora C. One-month sustained release microspheres of 125I-bovine calcitonin. In vitro-in vivo studies. J Control Release 59 1 (1999) 55-62
11. Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 372 9645 (2008) 1240-1250
12. Gallwitz B., Ropeter T., Morys-Wortmann C., Mentlein R., Siegel E.G., and Schmidt W.E. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul Pept 86 1-3 (2000) 103-111
13. Green B.D., Mooney M.H., Gault V.A., Irwin N., Bailey C.J., Harriott P., et al. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 180 3 (2004) 379-388
14. Hargrove D.M., Nardone N.A., Persson L.M., Parker J.C., and Stevenson R.W. Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 44 9 (1995) 1231-1237
15. Holst J.J. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10 6 (1999) 229-235
16. Holst J.J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18 6 (2002) 430-441
17. Hui H., Zhao X., and Perfetti R. Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. Diabetes Metab Res Rev 21 4 (2005) 313-331
18. Kieffer T.J., and Habener J.F. The glucagon-like peptides. Endocr Rev 20 6 (1999) 876-913
19. Kim D., MacConell L., Zhuang D., Kothare P.A., Trautmann M., Fineman M., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30 6 (2007) 1487-1493
20. Knudsen L.B., and Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318 2-3 (1996) 429-435
21. Meier J.J., Nauck M.A., Kranz D., Holst J.J., Deacon C.F., Gaeckler D., et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53 3 (2004) 654-662
22. Mentlein R. Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides. Regul pept 85 1 (1999) 9-24
23. Morita T., Horikiri Y., Yamahara H., Suzuki T., and Yoshino H. Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture. Pharm Res 17 11 (2000) 1367-1373
24. Morita T., Sakamura Y., Horikiri Y., Suzuki T., and Yoshino H. Protein encapsulation into biodegradable microspheres by a novel S/O/W emulsion method using poly(ethylene glycol) as a protein micronization adjuvant. J Control Release 69 3 (2000) 435-444
25. Nathan D.M., Schreiber E., Fogel H., Mojsov S., and Habener J.F. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15 2 (1992) 270-276
26. Nielsen L.L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Disc Today 10 10 (2005) 703-710
27. O'Hart F.P., Mooney M.H., Kelly C.M., McKillop A.M., and Flatt P.R. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36) amide in obese diabetic ob/ob mice. Regul Pept 96 3 (2001) 95-104
28. Sánchez A., Tobío M., González L., Fabra A., and Alonso M.J. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 18 3-4 (2003) 221-229
29. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2 11 (1996) 1254-1258
30. Tobío M., Nolley J., Guo Y., McIver J., and Alonso M.J. A novel system based on a poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm Res 16 5 (1999) 682-688
31. Weir G.C., Mojsov S., Hendrick G.K., and Habener J.F. Glucagonlike peptide 1(7-37) actions on endocrine pancreas. Diabetes 38 3 (1989) 338-342
32. Xiao Q., Giguere J., Parisien M., Jeng W., St-Pierre S.A., Brubaker P.L., et al. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 40 9 (2001) 2860-2869
33. Yin D., Lu Y., Zhang H., Zhang G., Zou H., Sun D., et al. Preparation of glucagon-like peptide-1 loaded PLGA microspheres: characterizations, release studies and bioactivities in vitro/in vivo. Chem Pharm Bull (Tokyo) 56 2 (2008) 156-161
34. Zander M., Madsbad S., Madsen J.L., and Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 9309 (2002) 824-830